JPS5810057A - Automatic blood treating apparatus - Google Patents

Automatic blood treating apparatus

Info

Publication number
JPS5810057A
JPS5810057A JP56106860A JP10686081A JPS5810057A JP S5810057 A JPS5810057 A JP S5810057A JP 56106860 A JP56106860 A JP 56106860A JP 10686081 A JP10686081 A JP 10686081A JP S5810057 A JPS5810057 A JP S5810057A
Authority
JP
Japan
Prior art keywords
body temperature
core body
blood processing
dialysis
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56106860A
Other languages
Japanese (ja)
Inventor
野田 俊彬
川村 尭夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikkiso Co Ltd
Original Assignee
Nikkiso Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikkiso Co Ltd filed Critical Nikkiso Co Ltd
Priority to JP56106860A priority Critical patent/JPS5810057A/en
Publication of JPS5810057A publication Critical patent/JPS5810057A/en
Pending legal-status Critical Current

Links

Landscapes

  • External Artificial Organs (AREA)

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 本発明は血液を浄化するいわゆる血液処理装置において
、患者の深部体温を計測し、その値により血液処理の諸
条件を自動制御する自動血液処理装置に関するものであ
る。以下血液処理装置の代表的な人工腎臓を例に説明す
る。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an automatic blood processing apparatus for purifying blood, which measures a patient's core body temperature and automatically controls blood processing conditions based on the measured value. The following describes an example of an artificial kidney, which is a typical blood processing device.

人工腎臓装置の゛役割は、血液中の老廃物あるいは水分
を除去することにある。従来透析液としてはアセテート
イオンを用いたアセテート透析が行われて来たが、透析
牛血圧低下、頭痛、はきけ、けいれん、発熱などの不均
衡症候群が発生し、患者の苦痛は大きかった。そのため
、これらの不均衡症候群を改善するべく、アセテートイ
オンの代りに炭酸水素イオンを主体とするバイカーボ透
析あるいは、アセテート透析液並びにパイカーボ透析液
に塩化すtリウム水溶液(時として炭酸水素ナトリウム
水溶液)を注入するいわゆる高すFリウム透析などが試
みられ大きな成果を挙げている。
The role of an artificial kidney device is to remove waste products or water from the blood. Conventionally, acetate dialysis has been performed using acetate ions as the dialysate, but this has caused imbalance syndromes such as decreased blood pressure, headache, nausea, convulsions, and fever in the dialysis cow, causing great pain to patients. Therefore, in order to improve these imbalance syndromes, bicarbodialysis mainly uses bicarbonate ions instead of acetate ions, or thorium chloride aqueous solution (sometimes sodium bicarbonate aqueous solution) is added to acetate dialysate and picarbodialysate. So-called high F dialysis, which involves injection, has been attempted with great success.

確かにこれらの方法は多くの患者にとって朗報でありほ
とんどの不均衡症候群は激減した。しかしながら、一部
の患者は完全に不均衡症候群から脱却出来ず、依然とし
て透析中の苦痛、不快感に悩まされている。また、患者
のその日の体調によっては不均衡症候群が現われること
があり、同じ条件でもある日は良いが、ある日は悪いと
言う患者もある。透析治療に関しては日夜努力され、改
善が試みられ、計画除水、透析ろ過、ろ過などいろいろ
な透析手法も行われているが、現在の透析技術では上記
手法以外で決定的に有効な方法は見当らないと言われて
いる。
Indeed, these methods have been good news for many patients, and most disequilibrium syndromes have been dramatically reduced. However, some patients cannot completely escape from the imbalance syndrome and still suffer from pain and discomfort during dialysis. In addition, an imbalance syndrome may appear depending on the patient's physical condition that day, and some patients may say that some days are good and others are bad even under the same conditions. Regarding dialysis treatment, efforts are being made day and night to improve it, and various dialysis methods such as planned water removal, diafiltration, and filtration are being used, but with current dialysis technology, no definitively effective method other than the above methods has been found. It is said that there is no.

従って、その患者に最も適切な透析9法を適用している
にも拘らず不均衡症候群が発生した場合は、その時点で
血流量を下げるとか、限外ろ過量を下げるとか、あるい
は塩化ナトリウム水溶液注入量を若干多くして、ナトリ
ウム濃変ヲ少し高めにするなどの処置を請じているのが
実情である。
Therefore, if an imbalance syndrome occurs despite applying the most appropriate dialysis method to the patient, it is recommended to reduce the blood flow, reduce the ultrafiltration rate, or use aqueous sodium chloride solution. The reality is that the patient is being asked to take measures such as slightly increasing the injection volume and increasing the sodium concentration.

また症状によっては、適切な投与剤を注入することもあ
る。
Depending on the symptoms, appropriate medication may also be injected.

ここで重要なことは、上に述べた処置はいずれも透析中
の患者の気分が悪くなってからの処置であること、もう
一つは技師、ナース、患者のいずれかが手動でしかも大
凡の感覚による定性的な処置であることである。
What is important here is that all of the above-mentioned treatments are performed after the patient is feeling unwell during dialysis, and the second thing is that either the technician, nurse, or patient must perform manual and general procedures. It is a qualitative treatment based on the senses.

患者の不均衡症候群の原因は、主に浸透圧の急激な変化
と血流量の低下と言われる。不均衡症候群が発生した時
の症状は、血圧低下、頭痛、はきけ、けいれん、発熱な
どであるがこれに伴って体調に何らかの変化を来たす。
The causes of imbalance syndrome in patients are said to be mainly rapid changes in osmotic pressure and decreased blood flow. Symptoms when an imbalance syndrome occurs include a drop in blood pressure, headache, nausea, convulsions, and fever, which also causes some changes in physical condition.

体表面混炭、脈拍、血圧、血流量、静脈圧(中心)など
の変化がそれである。しかしこれらの変化はいずれも結
果であって、これらを測定して処置したのでは不均衡症
候群の発生を事前に防止することは不可、能である。
These include changes in body surface carbon content, pulse rate, blood pressure, blood flow, and venous pressure (center). However, all of these changes are results, and it is impossible to prevent the occurrence of imbalance syndrome by measuring and treating them.

本発明者は、鋭意研究した結果、予知できる評価因子と
して深部体温に着目し、これによって不均衡症候群の事
前処置が可能になることを確認した0 従って本発明の一般的な目的は、本発明者Iこれら−の
欠陥を充分に検討し、不均衡症候群をある程度予知し、
これを定量的にとらまえ具体的な処置を自動的に行う方
法・装置を開発し、患者にとって極めて楽な透析治療を
可能ならしめることにある。また、本発明の別の目的は
、血液処理中の患者の深部体温を計測し、該深部体温の
値により血液処理治療における諸条件を自動制御するこ
とを特徴とする自動血液処理装置を提供することにある
。ここで血液処理装置とは、血液透析のみならず血液透
析ろ過、血液ろ過あるいはこれらの応用、さらには血漿
分離装置などを言う。
As a result of intensive research, the present inventors have focused on core body temperature as a predictive evaluation factor, and have confirmed that this makes it possible to pre-treat imbalance syndromes. Therefore, the general purpose of the present invention is to Those who have carefully considered these deficiencies and can predict the imbalance syndrome to some extent,
Our goal is to quantitatively understand this and develop a method and device that automatically performs specific treatments, thereby making dialysis treatment extremely easy for patients. Another object of the present invention is to provide an automatic blood processing device that measures the core body temperature of a patient during blood treatment and automatically controls various conditions in blood treatment treatment based on the value of the core body temperature. There is a particular thing. Here, the blood processing device refers not only to hemodialysis, but also to hemodiafiltration, hemofiltration, or applications thereof, and furthermore, plasma separation devices.

通常、該深部体温はその患者の症状によって異なる。中
枢深部体温(前額、胸部などの深部体1)はあまり大き
な変化はしないが、末梢深部体温(手、掌、足などの深
部体温)は顕著に変化する。
Typically, the core temperature varies depending on the patient's condition. Although the central core body temperature (deep body temperature 1 such as the forehead and chest) does not change significantly, the peripheral core body temperature (the core body temperature of the hands, palms, feet, etc.) changes significantly.

従って本発明においては、深部体温計により、深部体温
を計測し、末梢深部体温あるいは〔(中枢深部体温)−
(末梢深部体温)〕により症状を事前に評価し、その症
状に適した処置を行うものである。さらに具体的には末
梢深部体温あるいは〔(中枢深部体温)−(末梢深部体
温)〕の変化に応じて血流量、限外ろ過あるいは補液量
、塩化ナトリウム水溶液注入量、投与剤注入量を自動的
に変化させることにより患者の不均衡症候群を事前に改
善せんとするーものである。
Therefore, in the present invention, core body temperature is measured using a core body thermometer, and peripheral core body temperature or [(central core body temperature) -
(peripheral core body temperature)] to evaluate the symptoms in advance and take appropriate treatment for the symptoms. More specifically, blood flow, ultrafiltration or fluid replacement volume, sodium chloride aqueous solution injection volume, and drug injection volume are automatically adjusted according to changes in peripheral core body temperature or [(central core body temperature) - (peripheral core body temperature)]. The aim is to improve the patient's imbalance syndrome in advance by changing the

の時などでは中枢並びに末梢深部体温のいずれか/いず
れも上昇することがある。そのため制御方法は低下か上
昇かの判断によるのではなく変化値の絶対値による方法
を取らなければならな゛い。さらに制御方法は末梢深部
体温あるいは〔(中枢深部体温)−(末梢深部体温)〕
を計測し、この値によって血流量、限外ろ過量あるいは
補液量、塩化ナトリウム水溶液注入量、投与剤注入量を
階段的あるいは比例的に制御するのが簡単であり好まし
い。もちろん、必要に応じて他の微分、積分制御を行っ
てもよい。通常用いられ・る深部体温針を所定の身体部
位に装着して深部体温を計測し、この電気信号を増巾器
により所定の値に増巾した後、血液ポンプ、限外ろ過量
または除水量あるいは補液量、塩化ナトリウム水溶液注
入量′あるいはまた投与剤注入量等を制御する制御回路
により自動制御することによって目的は達せられる。
In some cases, central and peripheral core body temperature may rise. Therefore, the control method must be based on the absolute value of the change value, rather than on the determination of whether it is a decrease or increase. Furthermore, the control method is peripheral core body temperature or [(central core body temperature) - (peripheral core body temperature)]
It is easy and preferable to measure the amount of blood flow, ultrafiltration amount or fluid replacement amount, sodium chloride aqueous solution injection amount, and administration agent injection amount in a stepwise or proportional manner based on this value. Of course, other differential and integral control may be performed as necessary. A commonly used deep body temperature needle is attached to a specific body part to measure the core body temperature, and this electrical signal is amplified to a predetermined value using an amplification device. Alternatively, the objective can be achieved by automatic control using a control circuit that controls the amount of fluid replacement, the amount of aqueous sodium chloride solution injected, or the amount of drug injected.

また、深部体温については中枢深部体温のみを計測、評
価してもよいし、中枢深部体温、末梢深部体温、〔(中
枢深部体温)−(末梢深部体型)〕の組合せによって制
御することもできる。血液処理治療特に透析における種
々の不均衡症候群は患者の精神的なものによっても大き
く左右されるため極めてやっかいなものとされているが
、本発明に係わる自動血液処理装置によれば事前にこれ
を一子知し処理することが可能となり、非常に安心して
楽な治療を受けることができる。
Further, regarding core body temperature, only central core body temperature may be measured and evaluated, or it may be controlled by a combination of central core body temperature, peripheral core body temperature, and [(central core body temperature) - (peripheral core body shape)]. Various imbalance syndromes in blood processing treatments, especially dialysis, are considered extremely troublesome as they are greatly influenced by the patient's mental health, but the automatic blood processing device of the present invention can prevent these symptoms in advance. It is now possible to treat children with each other and receive treatment with great peace of mind and ease.

本発明は従来にない全く新らしい考え方に基づく画期的
な優れた血液処理装置である。
The present invention is an epoch-making and excellent blood processing device based on a completely new concept that has never existed before.

第1図は本発明に係わるブロック図である。lは患者、
Jは患者に装着される通常使府されてい巾する増巾器、
グは増巾された電気信号により制御を行う制御器、夕は
操作部である。操作部jは通常透析装置tに内蔵される
が外部に設置されることもある。
FIG. 1 is a block diagram according to the present invention. l is patient,
J is a widening device that is usually attached to a patient;
The main part is a controller that performs control using amplified electrical signals, and the main part is an operation part. The operating section j is usually built into the dialysis device t, but may be installed externally.

以下に透析治療における具体例によって説明する。A specific example of dialysis treatment will be explained below.

実施例t ・透析開始時条件 透析液   ; アセテートl 流
量 ;  joo−wJ/m t11流量   ; −よOd 7m 除水量   ;  4’ 00 m / h r除水方
法  ; 除水ポンプ 透析器    ; ホローファイバ//w/・自動透析
装置制御法(比例制御) 上記透析条件で透析を開始し、末梢深部体温中が(±)
O1/υの変化に対して血液ポンプの回転数を制御する
ことにより血流量を比例的にj a/ 7m減少させる
Example t - Conditions at the start of dialysis Dialysate; acetate l Flow rate; joo-wJ/m t11 flow rate; -yoOd 7m Water removal amount; 4'00 m/hr Water removal method; Water removal pump dialyzer; Hollow fiber/ /w/・Automatic dialysis machine control method (proportional control) Dialysis is started under the above dialysis conditions, and the peripheral core temperature is (±)
By controlling the rotation speed of the blood pump with respect to the change in O1/υ, the blood flow is proportionally reduced by ja/7m.

拳結果 上記条件で透析を開始したところ、グ時間経過後に末梢
深部体温(1)は約tコ℃迄低下し、血流量は60−/
−減少してlりOW/−となった。
Results When dialysis was started under the above conditions, the peripheral core body temperature (1) decreased to approximately t°C after 3 hours, and the blood flow decreased to 60°C.
-Decreased to lOW/-.

その後は末梢深部体温はほぼ一定に落ちつき無事透析を
終了した。
After that, the peripheral core temperature stabilized and the dialysis was successfully completed.

実施例よ ・透析開始時条件 透析液  ; アセテートl 流量
;  !00d/wig 血流量  ;  200w1/m 除水量  1AOO@I/hr 除水方法 ; 除水ポンプ 透析器   ;  ホローファイバt3vl・自動透析
装置制御方法(コ位置制御)上記Jt村条件で透析を開
始し、〔中枢深部体温(前額)−末梢深部体1(E5)
が(±> 0. J t+以上の変化に対して除水ポン
プの回転数を制御することにより除水量を、300d/
hr に切替える。
Example・Conditions at the start of dialysis Dialysate; Acetate l Flow rate; ! 00d/wig Blood flow rate; 200w1/m Water removal rate 1AOO@I/hr Water removal method; Water removal pump dialyzer; Hollow fiber T3VL/automatic dialysis device control method (co-position control) Dialysis was started under the above Jt village conditions, [Central core body temperature (forehead) - peripheral core body 1 (E5)
By controlling the rotation speed of the water removal pump for changes of (±> 0. J t+ or more), the water removal amount can be reduced to 300 d/
Switch to hr.

・結果 上記透析条件を設定し、計コゲ回の透析回数で計/ヂ回
の不均衡症候群(主に頭痛、はきけ)を発生した患者を
選び計22回の本発明に係わる           
 透析を行って、不均衡症候群の発生類、74較したと
ころ、本発明に係わる透析による不均衡症候群の発生回
数は2回に激減し、その2回の不均衡症候群も軽度のも
のであった。
・Results The above dialysis conditions were set, and a total of 22 patients were selected who developed an imbalance syndrome (mainly headaches and nausea) in the total number of dialysis sessions.
When comparing the number of occurrences of disequilibrium syndrome after dialysis, the number of occurrences of disequilibrium syndrome due to dialysis according to the present invention was drastically reduced to two, and the two instances of disequilibrium syndrome were also mild. .

実施例1 ・透析開始時条件 透析液   ; アセテートl 流
量 ;  !10d/− 血流量    ; ココO−/− 限外ろ過量 ; /、 / 00 ’/ hr限外ろ過
方法 ; 限外ろ過圧 補液量   ;  7!Ovd/hr 補液方法  ; 補液ポンプ 透析器   ; 積層型tJ d ・自動透析装置制御方法(2位置制御)上記条件で透析
を開始し、〔中枢深部体1(1m部)−末梢深部体温(
9〕が(±)0.1℃以上の変化に対して補液ダンプの
回転数を制御することにより、補液量を/、 000 
wl/ hrに切替える。
Example 1 - Conditions at the start of dialysis Dialysate; acetate l Flow rate; ! 10d/- Blood flow; Coco O-/- Ultrafiltration amount; /, / 00'/hr Ultrafiltration method; Ultrafiltration pressure replacement fluid amount; 7! Ovd/hr Fluid replacement method; Replacement pump dialyzer; Stacked type tJ d ・Automatic dialysis device control method (2-position control) Dialysis is started under the above conditions, [Central deep body 1 (1 m part) - Peripheral deep body temperature (
9] By controlling the rotation speed of the replacement fluid dump for changes of (±)0.1°C or more, the amount of replacement fluid can be adjusted to /, 000
Switch to wl/hr.

・結果 上記透析条件で透析を開始した。3.5時間経過後に〔
中枢深部体温(yi部)−末梢沖部体温く足)〕が約0
.6℃低下し補液量は/、000d/brに切替わりそ
のまま着率透析を終了した。
-Results Dialysis was started under the above dialysis conditions. After 3.5 hours [
Central core body temperature (yi part) - peripheral offshore body temperature (feet)] is approximately 0
.. The temperature decreased by 6° C., and the amount of replacement fluid was changed to 1,000 d/br, and the deposition rate dialysis was terminated.

実施例グ e透析開始縛条件 透析液   ; アセテートr 流
量 ; 了00d/m 〃 ナトリウ42i    / 3 j m 1cq/
1血流量   ;  200d1m 除水量   ;  j 00 d / hr除水方法 
 ; 除水ポンプ 透析器    ;  ホローアアイバ/Id・自動透析
装置制御方法(λ位置制御)上記透析条件で透析を開始
し、末梢深部体瀉促)が/υ以上の変化に対して透析液
ナトリウム轡変変更のための塩化ナトリウム水溶液(1
0%)を注入する注入ポンプの回転数を制御することに
より、透析液ナトリウム濃匣を/ ! ! m Kq/
jに切替える。
Example (e) Conditions for starting dialysis Dialysate; acetate; flow rate; 00d/m;
1 blood flow; 200 d1m water removal amount; j 00 d/hr water removal method
; Water removal pump dialyzer; Hollow Aiba/Id/Automatic dialysis device control method (λ position control) Start dialysis under the above dialysis conditions, and adjust the dialysate sodium change when the peripheral deep body dialysis) changes by more than /υ. Sodium chloride aqueous solution for modification (1
By controlling the rotational speed of the infusion pump to inject (0%) /! ! m Kq/
Switch to j.

・結果 上記透析条件で透析を開始したところ、3.5時間経過
後に末梢深部体WA(足つが約/、/℃低下し、塩化す
) IJウム水溶液(10n>の注入量が変化して透析
液ナトリウム濃!は/ j j mKq/1に切替わり
そのまま何ら不均衡症候群も発生せず無事透析を終了し
た。
・Results When dialysis was started under the above dialysis conditions, after 3.5 hours the distal deep body WA (foot pressure decreased by about /, /℃ and chloride). The liquid sodium concentration was changed to / j j mKq/1, and the dialysis was successfully completed without any imbalance syndrome occurring.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図は本発朋に係わるブロック図である。 FIG. 1 is a block diagram relating to the present invention.

Claims (5)

【特許請求の範囲】[Claims] (1)血液中の老廃物あるいは水分を除去するいわゆる
血液処理装置において、血液処理中の患者の深部体fl
p (Deep Body Temperaturs)
を計測し、該深部体温の値により血液処理治療における
諸条件を自動制御することを特徴とする自動血液処理装
置。
(1) In a so-called blood processing device that removes waste products or water from the blood, the patient's deep body fl.
p (Deep Body Temperatures)
1. An automatic blood processing device that measures the core body temperature and automatically controls various conditions in blood processing treatment based on the value of the core body temperature.
(2)  血液処理中の患者の深部体温の値により血流
量を自動制御することを特徴とする特許請求の範囲第(
1)項記載の自動血液処理装置。
(2) Claim No. 1, characterized in that blood flow is automatically controlled based on the value of the patient's core body temperature during blood treatment.
1) The automatic blood processing device described in section 1).
(3)  血液処理中の患者の深部体温の値により限外
ろ過量(UIFR)、除水量あるいは補液量を自動制御
することを特徴とする特許請求の範囲第(1)項記載の
自動血液処理装置。
(3) Automatic blood processing according to claim (1), characterized in that the ultrafiltration rate (UIFR), water removal rate, or fluid replacement rate is automatically controlled according to the value of the core body temperature of the patient during blood treatment. Device.
(4)  血液処理中の患者の深部体温の値により塩化
ナトリウム水溶液注入量を自動制御することを特徴とす
る特許請求の範囲第(1)項記載の自動血液処理装置。
(4) The automatic blood processing apparatus according to claim (1), wherein the amount of sodium chloride aqueous solution injected is automatically controlled according to the core body temperature of the patient during blood processing.
(5)  血液処理中の患者の深部体温の値により、投
与剤注入量を自動制御することを特徴とする特許請求の
範囲第(1)項記載の自動血液処理装置。
(5) The automatic blood processing apparatus according to claim (1), wherein the amount of the drug to be injected is automatically controlled based on the value of the core body temperature of the patient during blood processing.
JP56106860A 1981-07-10 1981-07-10 Automatic blood treating apparatus Pending JPS5810057A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56106860A JPS5810057A (en) 1981-07-10 1981-07-10 Automatic blood treating apparatus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56106860A JPS5810057A (en) 1981-07-10 1981-07-10 Automatic blood treating apparatus

Publications (1)

Publication Number Publication Date
JPS5810057A true JPS5810057A (en) 1983-01-20

Family

ID=14444319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56106860A Pending JPS5810057A (en) 1981-07-10 1981-07-10 Automatic blood treating apparatus

Country Status (1)

Country Link
JP (1) JPS5810057A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49111684A (en) * 1973-02-22 1974-10-24
JPS54144795A (en) * 1978-05-03 1979-11-12 Hakko Shiyouji Kk Device for cooling or heating transfusing liquid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49111684A (en) * 1973-02-22 1974-10-24
JPS54144795A (en) * 1978-05-03 1979-11-12 Hakko Shiyouji Kk Device for cooling or heating transfusing liquid

Similar Documents

Publication Publication Date Title
US6284141B1 (en) Method and system for preventing intradialytic symptomatology
EP1661591B2 (en) Apparatus for the purification of blood by means of hemodialysis and/or hemofiltration
US4500309A (en) Method for regional anticoagulation during extracorporeal dialysis
US20020068015A1 (en) Apparatus and method for control of ultrafiltration in extracorporeal treatment of blood
US7942842B2 (en) Apparatus and method for the treatment of blood
US20090192137A1 (en) Dialysis method
JPH11347116A (en) Blood refining apparatus
US11857715B2 (en) Extracorporeal blood treatment apparatus
JPS5810057A (en) Automatic blood treating apparatus
WO2003011367A1 (en) Blood purification apparatus for elevating purification efficiency
JPH0229962Y2 (en)
Vanholder et al. Single needle haemodialysis
Ronco et al. A new blood module for continuous renal replacement therapies
Von Herrath et al. Clinical aspects of hemofiltration
González-Fernández et al. PROTOCOL OF EXTRACORPOREAL PURIFICATION TECHNIQUES
McBride Taking the first steps in the development of peritoneal dialysis
Maeda et al. Hernodiafiltration With Sodium Concentration‐Controlled Dialysate
Aslam et al. Technologies to Monitor Dialysis Dose, Vascular Access Function and Improve Toxin Removal
Schneider et al. Clinical observations of the polyamide hollow-fiber hemofilter in hemofiltration systems
JP2024085569A (en) Blood Purification Device
JP2024085568A (en) Blood Purification Device
Patton et al. Peritoneal clearance of urea and potassium following experimental hypothermia.
JPH11332978A (en) Blood purification method and blood purification apparatus
Bellomo et al. The circuit and the prescription
Symons et al. 25 Hemodialysis